UTICA, N.Y. — ConMed Corporation (NASDAQ: CNMD) on Wednesday announced that it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from the NASDAQ Global Market.
The Utica–based surgical-device manufacturer expects to begin trading on the NYSE effective at the open of markets on Feb. 10, the firm announced.
“We are excited to be joining the NYSE on the actual day of ConMed’s 50th anniversary. With this move, we join the group of high-performing medical-device companies traded on the NYSE. We are grateful for the long and valued partnership with NASDAQ and look forward to a productive relationship with the NYSE,” Curt Hartman, CEO of ConMed, said in a statement.
(Sponsored)
Written Contracts for Freelance Workers Now Required
Originally planned for May, the requirements of New York State’s Freelance Isn’t Free Act (“FIFA”) became effective August 28, 2024. The law has flown under the radar for many employers. The
Embracing CHange Across the Generations
CH Insurance, Your LOCAL Partner for Insurance, Risk Management & Group Benefits Massive shifts have transformed workplaces and the world, including the insurance industry. From the advent of AI and
The company’s shares will continue to trade on the NASDAQ until the transfer is completed and will continue to trade under the ticker “CNMD” after the move to the NYSE.
“We are delighted to welcome ConMed, an innovator in the medical device industry, as it transfers its listing to the NYSE,” John Tuttle, vice chairman and chief commercial officer of NYSE Group. “We look forward to collaborating with the company and continuously delivering the benefits of our unique market model and world-class services.”
ConMed is a medical technology company that produces surgical devices and equipment for minimally invasive procedures. The firm’s products are used by surgeons and physicians in specialties that include orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology.
For the full year of 2019, ConMed posted net income of $28.6 million, or 97 cents a share, down 31 percent from $40.8 million, or $1.41 a share, during 2018.
Contact Reinhardt at ereinhardt@cnybj.com
